FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2074057580> ?p ?o ?g. }

• W2074057580 endingPage "199" @default.
• W2074057580 startingPage "196" @default.
• W2074057580 abstract "Our previous experimental studies have shown that the best approach to increase the biological anti-tumour activity of interleukin 2 (IL-2) is not co-administration of another cytokine, but the association with immunomodulating neurohormones, in an attempt to reproduce the physiological links between psychoendocrine and immune systems, which play a fundamental role in the regulation of the immune responses. In particular, the association with the pineal neurohormone melatonin (MLT) has been shown to cause tumour regressions in neoplasms that are generally non-responsive to IL-2 alone. To confirm these preliminary results, a clinical trial was performed in locally advanced or metastatic patients with solid tumours other than renal cell cancer and melanoma. The study included 80 consecutive patients, who were randomised to be treated with IL-2 alone subcutaneously (3 million IU day-1 at 8.00 p.m. 6 days a week for 4 weeks) or IL-2 plus MLT (40 mg day-1 orally at 8.00 p.m. every day starting 7 days before IL-2). A complete response was obtained in 3/41 patients treated with IL-2 plus MLT and in none of the patients receiving IL-2 alone. A partial response was achieved in 8/41 patients treated with IL-2 plus MLT and in only 1/39 patients treated with IL-2 alone. Tumour objective regression rate was significantly higher in patients treated with IL-2 and MLT than in those receiving IL-2 alone (11/41 vs 1/39, P < 0.001). The survival at 1 year was significantly higher in patients treated with IL-2 and MLT than in the IL-2 group (19/41 vs 6/39, P < 0.05). Finally, the mean increase in lymphocyte and eosinophil number was significantly higher in the IL-2 plus MLT group than in patients treated with IL-2 alone; on the contrary, the mean increase in the specific marker of macrophage activation neopterin was significantly higher in patients treated with IL-2 alone. The treatment was well tolerated in both groups of patients. This study shows that the concomitant administration of the pineal hormone MLT may increase the efficacy of low-dose IL-2 subcutaneous therapy." @default.
• W2074057580 created "2016-06-24" @default.
• W2074057580 creator A5006558782 @default.
• W2074057580 creator A5009513259 @default.
• W2074057580 creator A5026158008 @default.
• W2074057580 creator A5028874575 @default.
• W2074057580 creator A5030301955 @default.
• W2074057580 creator A5034334314 @default.
• W2074057580 creator A5042859107 @default.
• W2074057580 creator A5050814337 @default.
• W2074057580 creator A5052130645 @default.
• W2074057580 creator A5058179622 @default.
• W2074057580 creator A5059082117 @default.
• W2074057580 creator A5061179981 @default.
• W2074057580 date "1994-01-01" @default.
• W2074057580 modified "2023-10-06" @default.
• W2074057580 title "A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma" @default.
• W2074057580 cites W1975312084 @default.
• W2074057580 cites W1977047809 @default.
• W2074057580 cites W2002724941 @default.
• W2074057580 cites W2002760141 @default.
• W2074057580 cites W2033440285 @default.
• W2074057580 cites W2036275492 @default.
• W2074057580 cites W2115446789 @default.
• W2074057580 cites W2132805782 @default.
• W2074057580 cites W2270697554 @default.
• W2074057580 cites W2404730979 @default.
• W2074057580 cites W2422386627 @default.
• W2074057580 cites W265456471 @default.
• W2074057580 cites W2416927378 @default.
• W2074057580 doi "https://doi.org/10.1038/bjc.1994.34" @default.
• W2074057580 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1968792" @default.
• W2074057580 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8286206" @default.
• W2074057580 hasPublicationYear "1994" @default.
• W2074057580 type Work @default.
• W2074057580 sameAs 2074057580 @default.
• W2074057580 citedByCount "95" @default.
• W2074057580 countsByYear W20740575802012 @default.
• W2074057580 countsByYear W20740575802013 @default.
• W2074057580 countsByYear W20740575802014 @default.
• W2074057580 countsByYear W20740575802015 @default.
• W2074057580 countsByYear W20740575802018 @default.
• W2074057580 countsByYear W20740575802019 @default.
• W2074057580 countsByYear W20740575802020 @default.
• W2074057580 countsByYear W20740575802021 @default.
• W2074057580 countsByYear W20740575802022 @default.
• W2074057580 countsByYear W20740575802023 @default.
• W2074057580 crossrefType "journal-article" @default.
• W2074057580 hasAuthorship W2074057580A5006558782 @default.
• W2074057580 hasAuthorship W2074057580A5009513259 @default.
• W2074057580 hasAuthorship W2074057580A5026158008 @default.
• W2074057580 hasAuthorship W2074057580A5028874575 @default.
• W2074057580 hasAuthorship W2074057580A5030301955 @default.
• W2074057580 hasAuthorship W2074057580A5034334314 @default.
• W2074057580 hasAuthorship W2074057580A5042859107 @default.
• W2074057580 hasAuthorship W2074057580A5050814337 @default.
• W2074057580 hasAuthorship W2074057580A5052130645 @default.
• W2074057580 hasAuthorship W2074057580A5058179622 @default.
• W2074057580 hasAuthorship W2074057580A5059082117 @default.
• W2074057580 hasAuthorship W2074057580A5061179981 @default.
• W2074057580 hasBestOaLocation W20740575801 @default.
• W2074057580 hasConcept C121608353 @default.
• W2074057580 hasConcept C126322002 @default.
• W2074057580 hasConcept C134018914 @default.
• W2074057580 hasConcept C143998085 @default.
• W2074057580 hasConcept C203014093 @default.
• W2074057580 hasConcept C2777371288 @default.
• W2074057580 hasConcept C2777658100 @default.
• W2074057580 hasConcept C2778182776 @default.
• W2074057580 hasConcept C2778690821 @default.
• W2074057580 hasConcept C502942594 @default.
• W2074057580 hasConcept C71924100 @default.
• W2074057580 hasConcept C74172505 @default.
• W2074057580 hasConcept C8891405 @default.
• W2074057580 hasConcept C90924648 @default.
• W2074057580 hasConceptScore W2074057580C121608353 @default.
• W2074057580 hasConceptScore W2074057580C126322002 @default.
• W2074057580 hasConceptScore W2074057580C134018914 @default.
• W2074057580 hasConceptScore W2074057580C143998085 @default.
• W2074057580 hasConceptScore W2074057580C203014093 @default.
• W2074057580 hasConceptScore W2074057580C2777371288 @default.
• W2074057580 hasConceptScore W2074057580C2777658100 @default.
• W2074057580 hasConceptScore W2074057580C2778182776 @default.
• W2074057580 hasConceptScore W2074057580C2778690821 @default.
• W2074057580 hasConceptScore W2074057580C502942594 @default.
• W2074057580 hasConceptScore W2074057580C71924100 @default.
• W2074057580 hasConceptScore W2074057580C74172505 @default.
• W2074057580 hasConceptScore W2074057580C8891405 @default.
• W2074057580 hasConceptScore W2074057580C90924648 @default.
• W2074057580 hasIssue "1" @default.
• W2074057580 hasLocation W20740575801 @default.
• W2074057580 hasLocation W20740575802 @default.
• W2074057580 hasLocation W20740575803 @default.
• W2074057580 hasLocation W20740575804 @default.
• W2074057580 hasOpenAccess W2074057580 @default.
• W2074057580 hasPrimaryLocation W20740575801 @default.
• W2074057580 hasRelatedWork W1972126140 @default.
• W2074057580 hasRelatedWork W1980207544 @default.

• next